Mary Beth Pelletier

Dr. Mary Beth Pelletier is currently the Head of Quality Control for Intellia Therapeutics, a leading genome editing company whose mission is to develop potentially curative CRISPR/Cas9 gene editing treatments for people living with severe and life-threatening diseases. She has represented the Biotechnology Innovation Organization (BIO) on the ICH Expert Working Group for Q2(R2) and Q14 since 2018, driving development of harmonized global guidance on analytical procedure development and validation. Prior to Intellia, Mary Beth was Head of Quality for Biogen's Gene Therapy Manufacturing greenfield startup in Research Triangle Park, NC, and she previously led Biogen QC Analytical Technology where her team supported development, optimization, validation, transfer, troubleshooting, and lifecycle maintenance of analytical methods for Biogen’s biologics and gene therapy portfolio from Phase 1 throughout the commercial lifecycle. Prior to her positions at Biogen, Mary Beth worked in biologics formulation development and analytical development. Mary Beth earned a bachelor’s degree in chemistry from Northwestern University in Evanston, IL, a Ph.D. in chemistry from The Scripps Research Institute in La Jolla, CA, and an MBA from North Carol?.